NIH study aims to identify promising COVID-19 treatments for larger clinical trials
News briefing: Regeneron/Sanofi post positive PhIII Dupixent data in pediatric asthma; Vineti scores $33M Series C extension
Proactivity and partnership pay off for nursing homes in a pandemic, study suggests
Sorrento Adds Stem Cell Treatment To Covid-19 Pipeline; Shares Rise
Takeda group begins manufacturing Covid-19 plasma treatment ahead of approval
Covid-19 antibodies last at least three months; so do symptoms for many
These 2 Penny Stocks Could See Outsized Gains, Says Oppenheimer
UK biotech sector sets new record with more than £1bn investment in Q3
3 COVID-19 Antibody Stocks That Are Leading the Race
Spotlight on COVID-19 antibody therapies after Trump’s recovery
Eli Lilly In Gates Foundation Supply Deal For Covid-19 Antibodies
Goldman Sachs: 2 Strong Value Stocks to Buy Now
AstraZeneca Inks $486M US Support For Covid-19 Antibody Cocktail
Buy the Dip in Axovant Stock, Says Analyst
Eli Lily: Intriguing COVID-19 Story, but Questions Remain
What you – and doctors – should watch for if you have COVID-19
Eli Lilly and Gilead’s combination cuts COVID-19 recovery time
Regeneron joins Lilly in seeking emergency OK for COVID-19 antibody
Takeda-led Covid-19 plasma treatment enters clinical trial with first patient
Q&A with Fishawack Health’s Ross Toohey
Eli Lilly in deal to supply Covid-19 drugs to low-income countries
2020: A Year Defined By Healthcare & Digital
Gilead Inks EU Supply Deal For 500,000 Remdesivir Doses
Macro Briefing: 8 October 2020
Company of the Year 2020: Bristol-Myers Squibb — Patience Rewarded
Bayer 2020: End in sight
Boehringer Ingelheim 2020: Steady as they go
Gilead 2020: HIV … and COVID?
Amgen 2020: 40-Year-Old Pioneer
AstraZeneca 2020: Driven by Covid-19